IL135887A0 - Unducible phosphofructokinase and the warburg effect - Google Patents

Unducible phosphofructokinase and the warburg effect

Info

Publication number
IL135887A0
IL135887A0 IL13588798A IL13588798A IL135887A0 IL 135887 A0 IL135887 A0 IL 135887A0 IL 13588798 A IL13588798 A IL 13588798A IL 13588798 A IL13588798 A IL 13588798A IL 135887 A0 IL135887 A0 IL 135887A0
Authority
IL
Israel
Prior art keywords
ipfk
unducible
phosphofructokinase
warburg effect
cancer
Prior art date
Application number
IL13588798A
Other languages
English (en)
Original Assignee
Picower Inst Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Picower Inst Med Res filed Critical Picower Inst Med Res
Publication of IL135887A0 publication Critical patent/IL135887A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01105—6-Phosphofructo-2-kinase (2.7.1.105)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
IL13588798A 1997-10-31 1998-10-30 Unducible phosphofructokinase and the warburg effect IL135887A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/961,578 US6413939B1 (en) 1997-10-31 1997-10-31 Inducible phosphofructokinase and the Warburg effect
PCT/US1998/023155 WO1999023108A1 (en) 1997-10-31 1998-10-30 Inducible phosphofructokinase and the warburg effect

Publications (1)

Publication Number Publication Date
IL135887A0 true IL135887A0 (en) 2001-05-20

Family

ID=25504669

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13588798A IL135887A0 (en) 1997-10-31 1998-10-30 Unducible phosphofructokinase and the warburg effect

Country Status (10)

Country Link
US (4) US6413939B1 (ja)
EP (1) EP1042350B1 (ja)
JP (1) JP4369044B2 (ja)
AT (1) ATE417054T1 (ja)
AU (1) AU1370799A (ja)
CA (1) CA2308091A1 (ja)
DE (1) DE69840342D1 (ja)
ES (1) ES2319345T3 (ja)
IL (1) IL135887A0 (ja)
WO (1) WO1999023108A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413939B1 (en) 1997-10-31 2002-07-02 The Picower Institute For Medical Research Inducible phosphofructokinase and the Warburg effect
MY140679A (en) * 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
GB0216097D0 (en) * 2002-07-11 2002-08-21 Univ London Treatment of proliferative disorders
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
CN1839133A (zh) * 2003-08-22 2006-09-27 阿文尼尔药品公司 作为巨噬细胞移动抑制因子的抑制剂的取代的二氮杂萘衍生物及其在治疗人类疾病中的应用
WO2006065967A2 (en) * 2004-12-15 2006-06-22 General Atomics Allosteric enzyme coupled immunoassay (aecia)
AU2006227297A1 (en) * 2005-03-24 2006-09-28 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
US8662667B2 (en) * 2007-12-21 2014-03-04 Carl Zeiss Meditec Ag Ophthalmologic visualization system
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
EP2618849B1 (en) * 2010-09-20 2020-10-21 Caliper Life Sciences, Inc. Multivalent fluorescent probes
DK2532747T3 (en) * 2011-06-09 2016-01-25 Deutsches Krebsforsch Modulators of glycerol-3-phosphate dehydrogenase (GPD2) in therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0865495A4 (en) * 1995-10-24 2001-03-21 Garvan Inst Med Res GENE REGULATED BY PROGESTINE
US6413939B1 (en) 1997-10-31 2002-07-02 The Picower Institute For Medical Research Inducible phosphofructokinase and the Warburg effect

Also Published As

Publication number Publication date
ES2319345T3 (es) 2009-05-06
US6413939B1 (en) 2002-07-02
AU1370799A (en) 1999-05-24
US6596851B1 (en) 2003-07-22
CA2308091A1 (en) 1999-05-14
EP1042350A4 (en) 2003-01-02
EP1042350A1 (en) 2000-10-11
EP1042350B1 (en) 2008-12-10
ATE417054T1 (de) 2008-12-15
DE69840342D1 (de) 2009-01-22
US6255046B1 (en) 2001-07-03
JP4369044B2 (ja) 2009-11-18
JP2001521731A (ja) 2001-11-13
US20030228568A1 (en) 2003-12-11
WO1999023108A9 (en) 1999-08-19
WO1999023108A1 (en) 1999-05-14

Similar Documents

Publication Publication Date Title
IL135887A0 (en) Unducible phosphofructokinase and the warburg effect
Arora et al. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate
Zwelling et al. Kinetics of formation and disappearance of a DNA cross-linking effect in mouse leukemia L1210 cells treated with cis-and trans-diamminedichloroplatinum (II)
Millard et al. Determination of the DNA crosslinking sequence specificity of reductively activated mitomycin C at single-nucleotide resolution: deoxyguanosine residues at CpG are crosslinked preferentially
BG100293A (en) 2,8-disubstituted quinazolinons
PT876387E (pt) Utilizacao de roxitromicina para a preparacao de um medicamento para melhorar a actividade biologica e antiviral de inibidores da protease
Ovejera et al. Efficacy of 6-Diazo-5-oxo-l-norleucine and N-[N-γ-Glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice
GB9411671D0 (en) Tumor diagnosis and prognosis
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
ES2144391T3 (es) Derivados de alcoxi-4(1h)-piridona, sus procedimientos de preparacion y su utilizacion como medicamentos.
HUP9900905A2 (hu) D4-Vitamin származékok alkalmazása rák kezelésére szolgáló gyógyászati készítmények előállítására
WO2000047215A3 (en) Methods for anti-tumor therapy
DK0651636T3 (da) Kemoterapi for cancer
BR0008788A (pt) Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase
WO2001085219A3 (en) Identification, diagnosis, and treatment of breast cancer
Wick Levodopa/dopamine analogs as inhibitors of DNA synthesis in human melanoma cells
WO2002024947A3 (en) Cancer associated protein kinases and their uses
ES2114615T3 (es) Nueva sonda para el diagnostico de tumores o la terapia de tumores.
Li et al. Plant sterols as selective DNA polymerase β lyase inhibitors and potentiators of bleomycin cytotoxicity
HUP0300007A2 (en) Antibody with specificity for colon cancer
Rykova et al. Breast cancer diagnostics based on extracellular DNA and RNA circulating in blood
Mourelatos et al. Enhancement by methylxanthines of sister-chromatid exchange frequency induced by cytostatics in normal and leukemic human lymphocytes
Baguley et al. A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine
WO2001089449A3 (en) Phospholipase d effectors for therapy and screening
Riva et al. Effect of tetrahydrouridine on metabolism and transport of 1-β-D-arabinofuranosylcytosine in human cells